Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Financings Neutral

AI/ML Innovations Inc. Announces Grant of U.S. Patent Expanding Protection for AI-Driven ECG Analysis

AI cardiac analytics pilot-stage company secures patent and settles debt via equity issuance.

By The Northwire Desk — AI Analysis Jun 23, 2026 · 07:00 AIML · 0.05 AI-ML Innovations Inc.
Executive Summary
  • AI/ML Innovations Inc. (AIML) announced the grant of U.S. Patent No. 12,622,625 B2 for machine learning techniques applied to ECG analysis, covering denoising, rhythm classification, sample-level labeling, and report generation.
  • The company also settled past services and outstanding indebtedness by issuing 3,560,334 common shares at a deemed price of Cdn$0.05 per share.
  • The issuance is a related party transaction, with insiders expected to purchase 1,933,334 shares. It is exempt from formal valuation and minority shareholder approval under MI 61-101 and remains subject to Canadian Securities Exchange (CSE) approval.
Material Impact
  • The patent grant strengthens the intellectual property moat around AIML’s core cardiac platforms (MaxYield, CardioYield, Insight360), providing defensible protection for AI-driven signal processing and reporting. This is a standard developmental milestone for a pre-commercial health-tech firm.
  • The debt settlement reduces liabilities but introduces immediate dilution. Issuing 3.56M shares at $0.05 aligns with the recent trading range and does not raise new cash. It is a routine balance sheet management tactic for cash-constrained micro-caps.
  • No new revenue, contracts, or commercialization milestones are disclosed. The impact on near-term cash flow or profitability is neutral to slightly negative due to dilution.
AIML · Price
Company Overview
  • AI/ML Innovations Inc. is a digital health company focused on AI and machine learning applications for cardiac signal processing and analysis.
  • Through its subsidiary NeuralCloud Solutions Inc., the company develops platforms including MaxYield (ECG signal processing and denoising), CardioYield (AI-driven Holter monitoring and reporting), and Insight360 (analytics and visualization).
  • The business model targets ambulatory monitoring, telecardiology, wearable device integration, and clinical workflow automation.
  • The company is currently in a pre-commercialization phase, relying on clinical pilots, regulatory submissions, and strategic partnerships to validate its technology and drive future revenue.
Read the original news release →

More from AI-ML Innovations Inc.

May 11, 2026 · 22:20

AI/ML Innovations Secures Funding Amidst Dilutive Debt Settlements

Financings Apr 24, 2026 · 19:52

AIML Settles Debt with Equity as Liquidity Concerns Mount Amidst Unmonetized Pilots

Financings Apr 17, 2026 · 20:00

AI/ML Innovations Settles Debt with Equity Amidst Stagnant Valuation

Financings Mar 27, 2026 · 17:00

AI/ML Innovations Inc. Announces Closing of First Tranche of Private Placement to Raise $950,000

Financings Mar 12, 2026 · 19:30

AI/ML Innovations Inc. Announces Proposed Private Placement of Convertible Debentures

Financings Feb 12, 2026 · 07:00

AIML Subsidiary NeuralCloud Signs Non-Binding Agreement with Movesense to Pilot AI-Powered ECG and Holter Reporting

Production / Operations